Cadila to host TB awareness programmes across the country
Source : Inputs from India Blooms
New Delhi: An All India Awareness Programme on Tuberculosis was initiated by Cadila Pharmaceutical companies in New Delhi two days ago.
TB continues to be the No. 1 infectious disease in India, and one of the greatest public health challenges, killing 1 person every 2 minutes.
The awareness programme involving medical professionals, patients and youth through awareness rallies, in-clinic activities, skits/street plays is meant to highlight the relevance and significance of early diagnosis, regular dosage, completion of treatment and patient compliance to help control the disease.
According to India Blooms between March 21 and March 27 a series of activities that are being introduced would include: TB awareness rallies in 10 cities ,patient awareness programs, free TB Diagnosis, awareness talks on radio in 35 cities,TB awareness films will be shown at 220 locations across the country to highlight the positives and negatives of the deadly disease.
Tuberculosis an infectious bacterial disease is caused by Mycobacterium Tuberculosis, affecting lungs most commonly. It is a highly contagious bacterial infection that can spread quickly if not caught, isolated and treated early. A TB patient can infect through breathing, coughing, talking, singing, and sneezing .
According to a 2015 report published by the World Health Organisation, India has the highest no of TB inflicted in the world. Globally, 9.6 million people developed active TB in 2014, out of which 1.5 million died. As many as 2.5 million people were living with active TB in India in 2014. Over 70,000 were cases related to multi drug resistant TB (MDR-TB). This year the theme World TB day is ‘Find TB. Treat TB.' Working together to eliminate TB’.
Cadila Pharmaceuticals was one of the first companies to introduce Mycobutol and P-Zide in India and has been serving the Indian medical fraternity for over 30 years with a complete range of Anti-TB drugs.
Cadila Pharmaceuticals, driven by its vision of providing world-class, yet affordable medicines, had launched Risorine, the world’s first anti-tubercular drug with boosted Rifampicin, in the year 2009. Risorine uses Piperine which act as a bio enhancer in boosting the efficacy of Rifampicin and helps in improving patient compliance by lowering side effects. The drug has so far, been successfully administered to more than 1 Lakh TB patients.
Cadila Pharmaceuticals Ltd. is amongst the few companies worldwide that has continued to invest in research and development and is committed to Government of India’s ‘TB-Mission 2020’ which seeks to eradicate Tuberculosis from the country. This is also in line with World Health Organization’s (WHO) ambitious new 20-year (2016-2035) ‘End TB Strategy’, that envisions a world free of TB with zero deaths, disease and suffering.